BACKGROUND: The lethality of prostate cancer is due to the continuous growth of cancer initiating cells (CICs) which are often stimulated by androgen receptor (AR) signaling. However, the underlying molecular mechanism(s) for such AR-mediated growth stimulation are not fully understood. Such mechanisms may involve cancer cell-dependent induction of tumor stromal cells to produce paracrine growth factors or could involve cancer cell autonomous autocrine and/or intracellular AR signaling pathways. METHODS: We utilized clinical samples, animal models and a series of AR-positive human prostate cancer cell lines to evaluate AR-mediated growth stimulation of prostate CICs. RESULTS: The present studies document that stromal AR expression is not required for prostate cancer growth, since tumor stroma surrounding AR-positive human prostate cancer metastases (N = 127) are characteristically AR-negative. This lack of a requirement for AR expression in tumor stromal cells is also documented by the fact that human AR-positive prostate cancer cells grow equally well when xenografted in wild-type versus AR-null nude mice. AR-dependent growth stimulation was documented to involve secretion, extracellular binding, and signaling by autocrine growth factors. Orthotopic xenograft animal studies documented that the cellautonomous autocrine growth factors which stimulate prostate CIC growth are not the andromedins secreted by normal prostate stromal cells. Such cell autonomous and extracellular autocrine signaling is necessary but not sufficient for the optimal growth of prostate CICs based upon the response to anti-androgen plus/or minus preconditioned media. CONCLUSIONS: AR-induced growth stimulation of human prostate CICs requires AR-dependent intracellular pathways. The identification of such AR-dependent intracellular pathways offers new leads for the development of effective therapies for prostate cancer. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: The lethality of prostate cancer is due to the continuous growth of cancer initiating cells (CICs) which are often stimulated by androgen receptor (AR) signaling. However, the underlying molecular mechanism(s) for such AR-mediated growth stimulation are not fully understood. Such mechanisms may involve cancer cell-dependent induction of tumor stromal cells to produce paracrine growth factors or could involve cancer cell autonomous autocrine and/or intracellular AR signaling pathways. METHODS: We utilized clinical samples, animal models and a series of AR-positive humanprostate cancer cell lines to evaluate AR-mediated growth stimulation of prostate CICs. RESULTS: The present studies document that stromal AR expression is not required for prostate cancer growth, since tumor stroma surrounding AR-positive humanprostate cancer metastases (N = 127) are characteristically AR-negative. This lack of a requirement for AR expression in tumor stromal cells is also documented by the fact that humanAR-positive prostate cancer cells grow equally well when xenografted in wild-type versus AR-null nude mice. AR-dependent growth stimulation was documented to involve secretion, extracellular binding, and signaling by autocrine growth factors. Orthotopic xenograft animal studies documented that the cellautonomous autocrine growth factors which stimulate prostate CIC growth are not the andromedins secreted by normal prostate stromal cells. Such cell autonomous and extracellular autocrine signaling is necessary but not sufficient for the optimal growth of prostate CICs based upon the response to anti-androgen plus/or minus preconditioned media. CONCLUSIONS:AR-induced growth stimulation of human prostate CICs requires AR-dependent intracellular pathways. The identification of such AR-dependent intracellular pathways offers new leads for the development of effective therapies for prostate cancer. (c) 2009 Wiley-Liss, Inc.
Authors: Ivan V Litvinov; Donald J Vander Griend; Lizamma Antony; Susan Dalrymple; Angelo M De Marzo; Charles G Drake; John T Isaacs Journal: Proc Natl Acad Sci U S A Date: 2006-10-02 Impact factor: 11.205
Authors: M Nagabhushan; C M Miller; T P Pretlow; J M Giaconia; N L Edgehouse; S Schwartz; H J Kung; R W de Vere White; P H Gumerlock; M I Resnick; S B Amini; T G Pretlow Journal: Cancer Res Date: 1996-07-01 Impact factor: 12.701
Authors: Susan Dalrymple; Lizamma Antony; Yi Xu; Aarti R Uzgare; Julia T Arnold; Jurga Savaugeot; Lori J Sokoll; Angelo M De Marzo; John T Isaacs Journal: Cancer Res Date: 2005-10-15 Impact factor: 12.701
Authors: Samuel R Denmeade; Lori J Sokoll; Susan Dalrymple; D Marc Rosen; Alyssa M Gady; Debra Bruzek; Rebecca M Ricklis; John T Isaacs Journal: Prostate Date: 2003-03-01 Impact factor: 4.104
Authors: Sanaz Memarzadeh; Houjian Cai; Deanna M Janzen; Li Xin; Rita Lukacs; Mireille Riedinger; Yang Zong; Karel DeGendt; Guido Verhoeven; Jiaoti Huang; Owen N Witte Journal: Proc Natl Acad Sci U S A Date: 2011-04-25 Impact factor: 11.205
Authors: John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade Journal: Prostate Date: 2012-03-06 Impact factor: 4.104